Cardiff University Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (51)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Cardiff University - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Cardiff University. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “12” cancer drugs in clinical pipeline and majority of them are in phase-III.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Cardiff University - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Cardiff University - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Cardiff University. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “12” cancer drugs in clinical pipeline and majority of them are in phase-III.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Cardiff University - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Cardiff University

  1.1 Business Overview

  1.2 Cardiff University Cancer Pipeline Overview

 

2. Cardiff University Cancer Drugs in Preclinical Phase

  2.1 Cancer Therapeutics - Tiziana Life Sciences

  2.2 Cancer Therapeutics – NuCana

 

3. Cardiff University Cancer Drugs in Phase-I

  3.1 Pacritinib

  3.2 NUC 3373

 

4. Cardiff University Cancer Drugs in Phase-II

  4.1 MVA 5T4

  4.2 Tefinostat

 

5. Cardiff University Cancer Drugs in Phase-II/III

  5.1 Selinexor

 

6. Cardiff University Cancer Drugs in Phase-III

  6.1 Quizartinib

  6.2 NUC 1031

  6.3 Ganetespib

 

7. Cardiff University Cancer Drugs in Preregistration Phase

  7.1 Cytarabine/Daunorubicin Liposomal

  7.2 Vosaroxin

 

8. Discontinued in Cancer Drugs in Clinical Pipeline

  8.1 Polymer Therapeutics - ML Laboratories

 

9. Suspended in Cancer Drugs in Clinical Pipeline

  9.1 Gossypol – Bioenvision


Figure 1-1: Cardiff University Cancer Pipeline by Phase (%)

Figure 1-2: Cardiff University Cancer Pipeline by Phase (Number)

Figure 1-3: Cardiff University Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: Cardiff University Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)